Sunday, 4 October 2026European Markets

INCLUSIO SA/NV And BASSAC Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - inclusio sa/nv (inclu.br) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
inclusio sa/nv (inclu.br) €15.55 5.07% 16.11%
bassac (bass.pa) €41.60 3.37% 6.27%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. inclusio sa/nv (inclu.br)

5.07% forward dividend yield and 16.11% return on equity

inclusio sa operates as a real estate company in belgium. it focuses on affordable rental housing, housing for disabled, and social infrastructures. inclusio sa was incorporated in 2011 and is based in brussels, belgium.

earnings per share

as for profitability, inclusio sa/nv has a trailing twelve months eps of €4.5.

pe ratio

inclusio sa/nv has a trailing twelve months price to earnings ratio of 3.46. meaning, the purchaser of the share is investing €3.46 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.11%.

volume

today's last reported volume for inclusio sa/nv is 1369 which is 34.9% below its average volume of 2103.

moving average

inclusio sa/nv's value is higher than its 50-day moving average of €14.56 and way higher than its 200-day moving average of €13.65.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 22, 2024, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 5.07%.

more news about inclusio sa/nv.

2. bassac (bass.pa)

3.37% forward dividend yield and 6.27% return on equity

bassac société anonyme operates as a real estate development company primarily in france, belgium, germany, and spain. it offers residential buildings and houses, and commercial real estate, as well as prefabricated garages and land. the company was incorporated in 1972 and is headquartered in boulogne-billancourt, france. as of december 31, 2021, bassac société anonyme operates as a subsidiary of premier investissement sas.

earnings per share

as for profitability, bassac has a trailing twelve months eps of €5.81.

pe ratio

bassac has a trailing twelve months price to earnings ratio of 7.16. meaning, the purchaser of the share is investing €7.16 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.27%.

moving average

bassac's worth is below its 50-day moving average of €42.55 and under its 200-day moving average of €44.70.

volume

today's last reported volume for bassac is 1487 which is 96.43% above its average volume of 757.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 21, 2024, the estimated forward annual dividend rate is 1.5 and the estimated forward annual dividend yield is 3.37%.

more news about bassac.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com